?>

Wright Medical Group, Inc. Receives Department of Defense Funding for Clinical Study of OSTEOSET® T Bone Graft Substitute in Combat-Related Open Fracture Wounds

by: , Atlantic Wire
October 4, 2010

Category: Syndicated Industry News | RSS 2.0

ARLINGTON, Tenn.–(BUSINESS WIRE)–Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company, today announced it has been awarded a $2.4 million grant from the United States Department of Defense to fund a clinical study of OSTEOSET® T bone graft substitute pellets in combat-related open fracture wounds. OSTEOSET® T is a surgical grade calcium sulfate bone graft substitute impregnated with 4 percent tobramycin sulfate. It is available in pellet form and is physically



Add to digg
Add to del.icio.us
Add to Newsvine
Add to Reddit
Add to Google
Add to Yahoo My Web
Email this Article



Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter

Tags: , , , , , , , , ,


| Give a Comment | trackback

No Comments

Leave a Reply

You must be logged in to post a comment.

    Like Us On Facebook

  • Search This Site

    Custom Search
  • Upcoming Events

  • FREE Business Downloads

  • Widget Area

    This is widget area, add your widget here from your widget on appereance on your admin panel

>